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Plasmodium falciparum stage V gametocytes are responsible for parasite transmission, and
drugs targeting this stage are needed to support malaria elimination. We here screen the Tres
Cantos Antimalarial Set (TCAMS) using the previously developed P. falciparum female
gametocyte activation assay (Pf FGAA), which assesses stage V female gametocyte viability
and functionality using Pfs25 expression. We identify over 400 compounds with activities
o2 mM, chemically classiﬁed into 57 clusters and 33 singletons. Up to 68% of the hits are
chemotypes described for the ﬁrst time as late-stage gametocyte-targeting molecules.
In addition, the biological proﬁle of 90 compounds representing the chemical diversity
is assessed. We conﬁrm in vitro transmission-blocking activity of four of the six selected
molecules belonging to three distinct scaffold clusters. Overall, this TCAMS gametocyte
screen provides 276 promising antimalarial molecules with dual asexual/sexual activity,
representing starting points for target identiﬁcation and candidate selection.
DOI: 10.1038/ncomms15160 OPEN
1 Diseases of the Developing World (DDW), GlaxoSmithKline, Madrid, Tres Cantos 28760, Spain. 2 Department of Life Sciences, Imperial College of London,
London SW7 2AZ, UK. 3Molecular Discovery Research (MDR), GlaxoSmithKline, Madrid, Tres Cantos 28760, Spain. w Present address: Mahidol-Oxford
Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand and Centre for Tropical Medicine and Global
Health, Nufﬁeld Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK. Correspondence and requests for materials should be addressed to
E.H. (email: eherreros.a@gmail.com).
NATURE COMMUNICATIONS | 8:15160 | DOI: 10.1038/ncomms15160 | www.nature.com/naturecommunications 1
D
uring the last 10 years, there has been a substantial
intensiﬁcation of malaria control and prevention with the
implementation of both new vector control strategies and
chemotherapies. Nevertheless, the disease still remains a world-
wide public health challenge with Plasmodium falciparum causing
more than 214 million cases and 438,000 deaths per year1.
Malaria elimination is now being discussed as a realistic goal, but
new tools will be needed to achieve this aim, particularly in areas
of high transmission2. It is unlikely that malaria elimination can
be achieved in all contexts unless drugs and/or vaccines that
interrupt malaria transmission can be discovered, developed
and deployed3. Plasmodium stage V gametocytes are solely
responsible for malaria transmission. Thus, they constitute an
important target to block the parasite lifecycle through drug
administration to infected patients or asymptomatic carriers.
Since 2001, artemisinin-based combination therapies (ACTs)
have been recommended as ﬁrst-line treatment for uncompli-
cated falciparum malaria4. Although ACTs rapidly remove
asexual blood stages and early gametocytes from the patient,
their effectiveness against transmissible stage V gametocytes
remains unclear5–7. The only chemotherapeutic intervention
available for transmission interruption is low-dose (0.25mgkg 1)
primaquine8–11, recommended for use in areas of low
transmission as a single administration following ACT in
patients with P. falciparum malaria12. Higher doses may be
more efﬁcacious, but the use of primaquine for transmission
reduction is limited because of the potential for haemolysis in
individuals with glucose-6-phosphate dehydrogenase (G6PD)
deﬁciency, a relatively common genetic variation found in
malaria endemic areas13. When considered with the recently
reported cases of artemisinin resistance in the Greater Mekong
subregion that are threatening the effectiveness of ACTs14–16, the
discovery of safer drugs with new modes of action for malaria
treatment, prevention and transmission interruption is more
urgent than ever.
Several assays have been developed in recent years with the
objective of identifying drugs with transmission-blocking poten-
tial. Drugs with gametocytocidal activity have been detected using
diverse readouts, such as metabolic parameters (ATP, pLDH,
oxidoreduction)17–19 or mitochondrial damage and luciferase
reporters to track different gametocyte stages20,21. Most of these
assays are amenable to high throughput screening (HTS)
of large compound libraries20,22,23. Alternatively, a new
generation of gametocyte assays assess male and/or female
gamete formation as a broader metabolic framework within
which to determine drug activities modulating stage V
gametocyte functionality and viability. The idea was ﬁrst
reported by Delves and colleagues24, and subsequently
developed into a single assay, the P. falciparum Dual Gamete
Formation Assay (Pf DGFA)25. To date, a limited but diverse
group of studies24–27 suggest that results obtained in the Pf
DGFA usefully correlate with those of the ex vivo standard
membrane feeding assay (SMFA), but we remain alert to the need
to conﬁrm in vitro activities with those in vivo. The P. falciparum
female gametocyte activation assay (Pf FGAA) was the ﬁrst to be
scaled to 384-well format and validated for HTS28.
The Tres Cantos Antimalarial Set (TCAMS) is the largest
published collection of compounds active against P. falciparum
asexual blood stages29. In this study, the 13.5 K compounds in the
TCAMS are screened against stage V gametocytes in the
Pf FGAA28 to identify molecules effective against female gamete
formation. As both female and male gametes are required for the
development of mosquito stages, the parasite lifecycle may be
interrupted by solely targeting one of them. The objective of this
study is the discovery of new chemical diversity with activity
against both asexual blood stages and stage V (female)
gametocytes that may not only treat clinical symptoms but also
block malaria transmission.
Results
Hit identiﬁcation. The TCAMS was screened in the Pf FGAA
following the progression cascade described in Fig. 1. The 13,533
compounds were tested once at 2 mM single concentration using
48 h exposure, and 755 hits were identiﬁed using a mean plus 3
s.d.’s statistical cut-off, corresponding to 53% inhibition for this
screen. The hits were then re-tested in triplicate at the same
concentration resulting in 405 compounds with conﬁrmed
activity (3% ﬁnal hit rate). These compounds were then evaluated
in dose–response to determine their 50% inhibitory concentration
(IC50) (Supplementary Data 1). A good correlation was found
between the conﬁrmed hits and dose–response assay with more
than 80% of compounds possessing an IC50o2 mM. Additionally,
the cytotoxicity of these molecules was evaluated in mammalian
cells (HepG2) to determine their speciﬁcity for the parasite. Up to
120 compounds showed 50% inhibitory concentration (Tox50)
values above 10 mM (Supplementary Data 1).
In parallel, the set of conﬁrmed hits from the Pf FGAA screen
was cross-compared in the gametocyte ATP-depletion assay17, at
2 mM single concentration (Supplementary Data 1). This assay
monitors ATP levels as surrogate of gametocyte viability. We
observed that of the 405 compounds which were identiﬁed by the
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Figure 1 | Progression cascade of the TCAMS screen in the Pf FGAA. The different steps followed during the TCAMS screen as well as the number of
compounds identiﬁed in the ﬁrst phases and those selected for further proﬁling are shown. The ﬁrst four steps can be deﬁned as ‘hit identiﬁcation’. After
clustering, compounds are progressed to characterize their biological proﬁles and ﬁnally tested in the gold standard SMFA.
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Pf FGAA, only 129 compounds were also identiﬁed in the
ATP-depletion assay (40% inhibition cut-off) (Fig. 2).
To assess the chemical diversity provided by the Pf FGAA
screen, all conﬁrmed hits (405 compounds) were subjected to
computational analysis by applying a complete-linkage clustering
algorithm30, using a Tanimoto similarity threshold of 0.55. This
analysis identiﬁed 82 compound clusters and 63 singletons. After
chemical reviewing, they were reorganized based on structure
similarity into 57 clusters and 33 singletons. Initial triage was
based on simple and relaxed physicochemical properties
(molecular weight, lipophilicity, number of aromatic rings) and
selectivity index. Seven clusters comprising 97 compounds with
molecular weights above 600 gmol 1, clogP above 6 and HepG2
cytotoxicity o10 mM were ﬂagged and deprioritized from
further biological proﬁling. This left a total of 308 compounds
classiﬁed in 50 clusters, plus 33 singletons for consideration
(Supplementary Data 2). Clusters with three or less
representatives comprised more than 70% of the set, which is
indicative of the large chemical diversity identiﬁed in this screen.
A subset of 90 compounds representative of the new chemical
diversity was selected for further characterization of the
parasitological proﬁle (Supplementary Data 3). Some of these
chemical series are depicted in Fig. 3 and Supplementary Fig. 1.
Compound selection was performed taking into consideration the
top potency (IC50) and cytotoxicity (Tox50) values of compounds
in each cluster.
Hit proﬁling. The parasitological properties of the selected
molecules were further investigated to assess their speed of action
and activity against female gametocytes or gametes (Fig. 4 and
Supplementary Data 3).
To determine their speed of action, gametocytes were
preincubated with the compounds for only 24 h before inducing
gamete formation and their IC50 values compared to the
ones obtained in the 48 h preincubation described above
(Supplementary Data 3). There were 49 compounds that were
only active with a 48 h exposure (designated as slow-acting),
while 29 compounds additionally showed activity with only 24 h
exposure (designated as fast-acting) (Fig. 4).
Moreover, when the compounds were added 30min after
triggering gametocyte activation, 12 compounds prevented cell
surface expression of Pfs25 (designated as gamete-targeting;
Fig. 4). This suggests that these molecules target female gametes
directly, although this does not discount the possibility that they
are also active against stage V gametocytes.
Validation of the in vitro transmission-blocking activity.
To validate the transmission-blocking potential of the TCAMS
hits and assess the predictive value of the Pf FGAA as an in vitro
high throughput surrogate of full mosquito feeding, the
‘gold-standard’ SMFA was performed. Six compounds showing
different biological proﬁles, belonging to four distinct chemical
clusters, were selected based on their potencies in the Pf FGAA
(Supplementary Data 1, Table 1). For each compound, inhibition
of exﬂagellation of male gametocytes was measured. Five com-
pounds showed more than 50% inhibition while TCMDC-124559
displayed 30% inhibition (Fig. 5, Table 1). SMFAs were then
performed with a single dose at a concentration equivalent to the
respective Pf FGAA 90% inhibitory concentration (IC90) at the
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Figure 2 | Correlation graph of hits identiﬁed in the Pf FGAA screen compared to their activities in the ATP-depletion assay. 276 compounds
(green circles and all stars) out of the 405 hits were exclusively identiﬁed in the Pf FGAA while 129 compounds (grey circles) were active in both assays.
Stars represent those compounds further proﬁled: slow-acting (blue stars), fast-acting (yellow starts) and gamete-targeting (magenta stars). Compounds
tested in the SMFA are marked as big stars.
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48 h incubation time (Table 1). Compounds were tested in
duplicate in 2–3 independent experiments in the indirect format
of the assay, that is, gametocytes were exposed to the drug for
48 h before mosquito feeding to replicate a drug exposure time
equivalent to that used in the Pf FGAA. Five of these selected
compounds showed a reduction in oocyst prevalence of 58–100%
(Fig. 6a), and a reduction in oocyst intensity of 480% (Fig. 6b).
By contrast, TCMDC-124559 reduced prevalence and intensity by
o20% (Fig. 6a,b, respectively).
In vivo efﬁcacy and pharmacokinetics of selected molecules.
Two out of the six compounds progressed to SMFA, TCMDC-
123767 (cluster 30) and TCMDC-141154 (cluster 4), were
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Figure 3 | TCAMS chemical series representatives of the compound set further progressed. Scaffolds of 15 chemotypes, belonging to 24 of the
90 compounds proﬁled, that are within an appropriate physicochemical space (clogPo5, number of aromatic rings o3).
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evaluated in vivo in the Plasmodium berghei murine model31.
Selection criteria was based on the compound potencies in both
asexual stages and gametocytes in the Pf FGAA, as well as on
their transmission-blocking activity observed in the SMFA
(Table 1). Owing to compound availability, TCMDC-141154
had to be replaced by a close analogue from cluster 4: TCMDC-
140549 (Supplementary Data 3). Compounds were tested at
50mg kg 1 single dose 2-day oral treatment and efﬁcacy was
measured as a reduction of asexual blood stages parasitaemia
greater than 40% compared with the vehicle-treated mice.
P. berghei growth was not reduced above the threshold after
mice treatment with any of the two compounds (Fig. 7).
Additional in vitro ADME and in vivo pharmacokinetic studies
were then performed to explain the lack of activity of these two
compounds. TCMDC-123767 was rapidly eliminated in vivo and
was last detected in blood above the lower limit of quantiﬁcation
(LLOQ, 2.5 ngml 1) only 1 h post-administration. Supporting
this, it also showed high in vitro microsome clearance
(7.9mlmin 1 per g liver). TCMDC-140549 was estimated to
possess moderate permeability through artiﬁcial membranes
(170 nm s 1), which may drive a low oral bioavailability.
Discussion
To the best of our knowledge, this paper reports the largest
screening effort performed to date using an assay that utilizes
P. falciparum gamete formation as the endpoint. The TCAMS
library was screened in the Pf FGAA and 405 chemical-starting-
points for antimalarial transmission-blocking drug discovery were
identiﬁed. Further analysis of these molecules revealed that
276 compounds (25% with selectivity index 410) belonged to
chemotypes never described before as gametocyte-targeting
molecules.
Regarding the chemical diversity identiﬁed, a few of these
compounds showed similarity with classical antimalarial scaf-
folds, for example, 4-aminoquinoline (TCMDC-138933, cluster 7,
IC50¼ 0.76 mM) and diaminopyrimidine (TCMDC-137820, clus-
ter 25, IC50¼ 1.06 mM) (Supplementary Data 3). The majority
comprises novel chemotypes with good physicochemical proper-
ties. This TCAMS set of hits includes several scaffolds that have
been previously identiﬁed by GSK as promising antimalarial
starting points for drugs against parasite asexual stages32, and that
are or have been part of internal medicinal chemistry
programmes (Supplementary Fig. 1). These potential drugs can
now be prioritized with the added value of being gametocyte-
targeting. Interestingly, a preliminary analysis of hit structure
revealed that some of the compounds are closely related to the
GSK Published Kinase Inhibitor Set (PKIS)33 (Supplementary
Fig. 1), suggesting Plasmodium kinases as potential targets for
these molecules.
The original literature annotation for TCAMS was also
investigated. TCMDC-141611 is a compound patented by
SmithKline Beecham as an inhibitor of the Tie-2 tyrosine kinase
receptor, which is involved in angiogenesis. Despite the lack of a
classical tyrosine kinase family in the P. falciparum kinome34,
there is evidence for tyrosine phosphorylation being involved
in regulatory functions in the parasite35. TCMDC-142257 is
an antagonist of the Dopamine 2 receptor, a kind of G-protein-
coupled receptor, for which there is some bioinformatic evidence
in the P. falciparum genome36. Further investigations will be
necessary to understand the mechanisms of action of these
compounds and by publishing these structures we intend to
stimulate research in this area.
From the point of view of malaria drug discovery, the most
practical way to interrupt the Plasmodium lifecycle would be
through the clearance of transmissible stages present in the
peripheral bloodstream of infected patients. In this context, those
compounds with a fast-acting proﬁle would be preferred to those
requiring longer exposure times. Overall, almost 90% of the
compounds tested in this study exerted their effect in stage V
gametocytes (and asexual blood stages) but not in female gametes,
which revealed their potential utility for transmission-blocking
strategies. Further research would be required to determine if the
12 compounds active against female gametes also target stage V
gametocytes and so might have an added value as multi-stage
antimalarial drugs.
Six selected compounds with diverse biological and chemical
proﬁles were tested in the SMFA (Table 1). Four out of the six
tested compounds showed more than 80% block in transmission
(Fig. 6, Table 1), while TCMDC-124559 and TCMDC-125345 had
49 compounds
(31 clusters + 7 ST)
Gametocyte activation
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Stage V gametocytes Female gametes
24 h24 h
48h + 24h h + 24 h
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Slow-acting cmp
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Figure 4 | Diversity of biological proﬁles determined by use of different incubation times in the Pf FGAA. Stage V gametocytes were exposed to the
90 selected compounds for 24 or 48 h to determine the drug inhibitory speed of action. In addition, compounds were added after triggering gametocyte
activation to evaluate their activity in female gametes. The ﬁgure shows the number of compounds and chemical diversity classiﬁed under each category,
that is, slow-acting, fast-acting or gamete-targeting compounds.
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lower efﬁcacy, even though all compounds had IC50 values
between 0.16 and 0.5mM in the Pf FGAA. However, there was a
good correlation between inhibition of exﬂagellation, reduction in
oocyst intensity and block in transmission (Figs 5 and 6). This
suggests that compounds affecting both male and female gamete
formation may lead to a more efﬁcacious blockade of malaria
transmission.
Further in vivo evaluation of two selected molecules, TCMDC-
123767 and TCMDC-140549, in the P. berghei murine model31
showed an ED50 450mg kg 1 after a single dose 2-day
treatment (Fig. 7). Subsequent pharmacokinetic analysis
revealed very low exposure levels in blood for TCMDC-123767,
which might explain the lack of effect of this molecule in the
in vivo model. Given that both compounds showed a good
Table 1 | Biological and chemical proﬁle of the six compounds tested in the SMFA.
TCAMS ID Chemical
structure
Cluster
number
PfFGAA
IC50
(lM)
SMFA
concentration
(lM)
Inhibition of
exﬂagellation
(%)
Block in
transmission
(%)
Tox50
(lM)
Biological
proﬁle
TCMDC-
123767
30 0.16 1 88 83 100 Slow-
acting
TCMDC-
125345
18 0.36 1 50 60 39.82 Fast-
acting
TCMDC-
141698
11 0.44 1 84 82 4.79 Gamete-
targeting
TCMDC-
141070
4 0.53 2 99 88 28.96 Gamete-
targeting
TCMDC-
141154
4 0.21 1 97 93 11.9 Gamete-
targeting
TCMDC-
124559
18 0.5 1 30 15 4100 Fast-
acting
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parasitological proﬁle in vitro, further studies to improve stability
and bioavailability will be performed to address their potential
use as antimalarial drugs. Clearance of TCMDC-123767 and
TCMDC-140549 may be reduced by blockade of labile positions,
whereas solubility of TCMDC-123767 may be increased by
incorporation of polar and/or ionizable groups.
In conclusion, the Pf FGAA can identify potential transmis-
sion-blocking chemotypes which, due to the biological content
covered in this assay, were undetected by previous gametocyte-
based assays. The TCAMS library screen yielded 276 new
gametocyte-targeting molecules belonging to 57 diverse chemical
entities and 3 biological proﬁles. Nearly 25% of the hits identiﬁed
are within the appropriate physicochemical space (clogPo5,
number of aromatic rings o3) and will therefore be considered
for further progression, while other hits represent valuable
starting points as tool compounds to identify new modes of
action involved in the biology of Plasmodium transmission.
Methods
Gametocyte production. P. falciparum NF54 (originally isolated from an
imported malaria case in the Netherlands in the 1980s; BEI Resources, cat. no.
MRA-1000) asexual-stage culture was performed as described by Trager and
Jensen37. Cultures synchronized at the ring stage were used to start gametocyte
cultures (day 0) at 1% parasitaemia and 4% haematocrit in 200ml ﬁnal volume
using culture bottles (Nalgene 3110-42, Thermo Scientiﬁc). Complete culture
medium (RPMI 1640 supplemented with 25mM HEPES, 50 mgml 1
hypoxanthine, 2 g l 1 NaHCO3 and 10% pooled human male type Aþ serum)
was totally replaced daily for 14 days without fresh erythrocyte addition. Human
serum was obtained from Interstate Blood Bank, Aþ serotype; no aspirin 2 h
before drawing and no antimalarials 2 weeks before drawing. To ensure a stable
temperature at 37 C, which is crucial for gametocyte production and maturation,
pre-warmed medium and a slide warmer (XH-2001, Premiere) were used. Under
these conditions, parasitaemia reaches a peak of asexual stages on days 4–5, and the
ﬁrst gametocytes are differentiated in culture on day 6. Sexual-stage development
was monitored microscopically by Giemsa-stained thin blood smears at day 7
(mainly asexual stages and stages I to III gametocytes) and day 14 (stages IV and
V gametocytes).
Female gametocyte activation assay (Pf FGAA). Cultures showing mainly stage
V gametocytes were puriﬁed by differential sedimentation as previously reported28.
The gametocyte concentration was adjusted to plate 8,000 gametocytes per well
(100 ml per well) in 384-well poly-D-lysine coated plates (781946, Greiner Bio-One)
containing the compounds to test. Gametocytes were incubated with drugs for
TC
M
DC
-1
40
54
9
TC
M
DC
-1
23
76
7
–1.5
–1.0
–0.5
0.0
0.5
1.0
1.5
lo
g 1
0 
(%
 pa
ras
ite
mi
a) ED50
ED90
Qu
ini
ne
M
ef
lo
qu
in
e
Pi
pe
ra
qu
in
e
Ve
hi
cl
e
Experiment controls
Figure 7 | Effect of two TCAMS hits in the P. berghei in vivomouse model.
Each experiment included a control group treated with vehicle (green circle)
used as a reference to calculate the percentage of inhibition of parasitaemia
in peripheral blood (dotted red line). The response of standard antimalarials
in the same assay is also presented (blue, magenta and grey circles).
Represented data are the mean±s.e.m. log10 [% asexual blood stages at
day 4] of two mice per point.
TC
MD
C-1
41
07
0
TC
MD
C-1
24
55
9 
TC
MD
C-1
25
34
5
TC
MD
C-1
41
69
8
TC
MD
C-1
23
76
7
TC
MD
C-1
41
15
4
0
20
40
60
80
100
120
Ex
fla
ge
lla
tio
n
in
hi
bi
tio
n 
(%
)
Figure 5 | Exﬂagellation inhibition by six TCAMS compounds. Stage V
gametocyte cultures were exposed to 2 mM of TCMDC-141070 and 1mM of
the ﬁve remaining compounds for 48 h. The percentage inhibition was
determined compared to DMSO-treated controls. Compounds were then
progressed into SMFA to further determine the transmission blocking in
mosquitoes. Each bar represents mean value of two (TCMDC-125345,
TCMDC-141698, TCMDC-123767, TCMDC-141154) or three (TCMDC-
141070, TCMDC-124559) independent replicates with s.d.
TC
MD
C-1
41
07
0
TC
MD
C-1
24
55
9
TC
MD
C-1
25
34
5
TC
MD
C-1
41
69
8
TC
MD
C-1
23
76
7
TC
MD
C-1
41
15
4
0
20
40
60
80
100
120
Bl
oc
k 
in
 tr
an
sm
is
si
on
 (%
)
TC
MD
C-1
41
07
0
TC
MD
C-1
24
55
9
TC
MD
C-1
25
34
5
TC
MD
C-1
41
69
8
TC
MD
C-1
23
76
7
TC
MD
C-1
41
15
4
0
20
40
60
80
100
120
R
ed
uc
tio
n 
in
 o
oc
ys
t
in
te
ns
ity
 (%
)
a
b
Figure 6 | Effect of selected TCAMS compounds in the SMFA. The
following parameters were measured: (a) Transmission-blocking activity
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either 24 h or 48 h at 37 C (3% O2, 5% CO2 and 92% N2). Female gametocyte
activation was then triggered by temperature drop and addition of xanthurenic acid
(D120804, Sigma) as previously described24. To detect female gametes, monoclonal
anti-Pfs25 antibody38 4B7 (BEI Resources (formerly MR4), cat. no. MRA-315)
conjugated to the Cy3 ﬂuorochrome (GE Healthcare) was added to ookinete
medium (RPMI 1640 supplemented with 25mM HEPES, 50 mgml 1
hypoxanthine, 2 g l 1 NaHCO3, 100 mM xanthurenic acid and 20% human serum)
at a ﬁnal concentration of 0.5 mgml 1. Activated cultures were then kept at 26 C
for 24 h protected from light, and image acquisition was performed in the Opera
High-Content Screening System (PerkinElmer). Using  10 air objective, ﬁve
images per well were taken using 532 nm excitation. Images were analysed with a
Columbus image data storage and analysis system (PerkinElmer) based on a script
speciﬁcally designed for this assay that considers size, roundness and intensity of
ﬂuorescence of the female activated gametocytes.
Gametocytocidal ATP-depletion assay. ‘Viability’ of mature gametocytes was
determined using the gametocyte ATP bioluminiscence assay22. Brieﬂy, stages
IV–V gametocyte cultures were double-puriﬁed by differential sedimentation
followed by magnetic isolation17. Then, parasites (50ml per well containing 12,500
gametocytes) were added to compound pre-dispensed 384-well plates (781091,
Greiner Bio-One) and incubated at 37 C for 48 h (3% O2, 5% CO2 and 92% N2).
BacTiter-Glo kit (G8231, Promega) was used to determine the ATP levels of ‘live’
parasites according to the manufacturer’s instructions. After reagent addition (50 ml
per well), luminescence of the plates was measured using a microplate reader (HTS
counter Victor, Wallac).
Exﬂagellation assay. Exﬂagellation was measured as previously reported24 with
minor modiﬁcations. Using 5ml of day-14 gametocyte cultures, parasites were
incubated with the corresponding concentration for each compound in six-well
plates at 37 C (3% O2, 5% CO2 and 92% N2). After 48 h incubation, a 200ml
sample was spun down in a microfuge, the supernatant was carefully removed and
the pellet resuspended in 15 ml of pre-warmed ookinete medium. Parasites were
placed in Fast-Read disposable haemocytometer slides and, after 15min at room
temperature (22 C), exﬂagellation centres per ﬁeld were counted under  10
objective.
Standard membrane feeding assay (SMFA). Day-14 gametocyte cultures were
plated in pre-warmed six-well-plates (5ml per well) and were exposed to the
compounds (1mM or 2 mM ﬁnal concentration) for 48 h at 37 C (3% O2, 5% CO2
and 92% N2). Within this incubation time, 3ml of media were removed after the
ﬁrst 24 h and replenished with the same volume of fresh media with compound
added to obtain the required ﬁnal concentration. After 48 h of total exposure,
cultures were centrifuged at 2,500 g for 3min at 37 C, diluted 1:1 with 100%
packed volume of fresh erythrocytes and ﬁnally formulated as artiﬁcial mosquito
blood meals at 50% haematocrit with pre-warmed human serum. All steps were
performed at 37 C to avoid gametocyte activation. Four- to six-day old female
Anopheles stephensi mosquitoes (GlaxoSmithKline Insectary) were fed for 30min
via Paraﬁlm membrane attached to glass feeders (12831283, Fisher Scientiﬁc)
connected to a 37 C circulating water bath. Fed mosquitoes were maintained in an
incubator at 27 C and 75% relative humidity with 12 h light/dark cycles. Seven to
eight days post-feeding, mosquitoes with fully developed ovaries were dissected for
midguts, which were rinsed in a 0.2% mercury-dibromoﬂuorescein (63869, Fluka)
in water solution for 10min. Total number of oocysts in individual midguts were
counted using a light microscope (DM2000, Leica) under a  10 objective. The
percentage of block in transmission (reduction in prevalence) and the percentage of
reduction in mean oocyst intensity were calculated after normalizing to the control
DMSO-treated sample. Two to three independent SMFA experiments were
performed and two internal duplicates of 40 mosquitoes each were used per
compound. Mean oocyst intensities were not less than two oocysts per mosquito
and the prevalence of infection ranged from 70 to 90% in the fed mosquito control
groups. See complete experimental data set in Supplementary Table 1 and
Supplementary Note 1.
HepG2 cytotoxicity assay. Actively growing HepG2 cells (HB-8065, ATCC) were
detached from the culture surface and dispersed with 5ml of Eagle’s Minimum
Essential Media (supplemented with 10% FBS/1% NEAA solution/1% penicillin þ
streptomycin) by repeated pipetting. Cell suspension was added to 500ml of the
same medium at a ﬁnal density of 1.2 105 cellsml 1 and 25ml per well were
seeded in 384-well-plates with pre-dispended compounds (250 nl per well) using a
Multidrop combi dispenser (Thermo Scientiﬁc); this number of cells (typically
3,000 cells per well) ensures that new monolayers were not more than B50%
conﬂuent at the time of seeding. Cells were incubated at 37 C and 5% CO2 in a
humidiﬁed incubator for 48 h. After incubation, plates and CellTiter-Glo Reagent
(G7571, Promega) were equilibrated at room temperature for 30min before pro-
ceeding to develop the luminescent signal. Using a Multidrop combi dispenser,
25ml per well of the signal developer were added to the plates and after 10min at
room temperature for stabilization, plates were read on the ViewLux system
(Perkin Elmer).
Evaluation of in vivo antimalarial therapeutic efﬁcacy. Pathogen-free CD1 mice
(Hsd:ICR) were obtained from Harlan Interfauna Iberica (Barcelona, Spain). Eight
weeks old female CD-1 mice were infected intravenously with 107 infected ery-
throcytes (day 0). Dosing solutions were prepared in water containing 5% DMSO/
20% Captisol, at a target dose of 50mg kg 1. Mice received two oral doses once a
day according to their body weight (20ml kg 1) starting at day 2 after infection.
Control mice received the same treatment schedule with the vehicle used for the
compound preparation. Samples from mice peripheral blood were taken before
starting treatment and 24 h after ﬁnishing the dosing, to measure parasitaemia by
ﬂow cytometry, using the YOYO-1 staining39, to assess the reduction of
parasitaemia compared with the vehicle-treated mice.
In vivo pharmacokinetic studies. Female CD-1 mice (Harlan Interfauna Iberica)
at 8 weeks of age were used for single oral dose pharmacokinetic studies (n¼ 2).
Dosing solutions were prepared in 20% (v:v) Captisol in water, at a target dose of
50mg kg 1 (dose volume of 20ml kg 1). After oral dosing, blood samples (25 ml)
were collected at 30min, 1 h, 6 h and 8 h post dose for TCMDC-123767. All the
blood samples were diluted with 25 ml of an aqueous solution of saponine 1% (w:v),
and stored at  80 C until analysis. Mice blood samples were analysed for each
compound using a method upon protein precipitation followed by LC-MS/MS
analysis (Applied Biosystems). Data analysis of the concentration time proﬁles
was performed by noncompartmental methods by using WinNonLin Phoenix
Version 6.3.
Intrinsic clearance assay. Intrinsic clearance (CLi) values were determined in
mouse liver microsomes (M1000, XenoTech). Test compounds (ﬁnal concentration
0.5 mM) were incubated at 37 C for 45min in 50mM potassium phosphate buffer
(pH 7.4) containing 0.5mg microsomal protein per ml. The reaction was started by
addition of cofactor NADPH (N1630, Sigma) at 1mM ﬁnal concentration. The
ﬁnal concentration of organic solvent (DMSO) was limited to 0.25% of the ﬁnal
volume. At 0, 5, 15, 30, and 45min, an aliquot (100 ml) was taken, quenched
with acetonitrile containing an appropriate internal standard, and analysed by
HPLC-MS/MS (Applied Biosystems). CLi was determined from the ﬁrst-order
elimination constant by nonlinear regression, corrected for the volume of the
incubation and assuming 48 microsomal mouse protein per g liver. Values for
CLi were expressed as mlmin 1 per g liver.
Artiﬁcial membrane permeability assay (AMPA). It is a 96-well plate-based
assay that measures the speed of permeation of a compound (at 10 mM con-
centration) through a phospholipid membrane, consisting in 1.8% egg L-a-phos-
phatidylcholine (830051, Avanti Polar Lipids) and 1% cholesterol (C8667, Sigma)
dissolved in n-decane (D0011, TCI American). Phosphate buffer (50mM
Na2HPO4 with 0.5% 2-hydroxypropyl-b-cyclodextrin), pH 7.05, is added to the top
and bottom of the plate (S5EJ046I08, MilliPore Corp.). The lipids are allowed to
form bilayers across the small holes in the ﬁlter and compound concentration is
measured 3 h later in both donor and the acceptor compartments by HPLC
(Agilent 1100 LC). Permeability (P) (nm s 1) is calculated using the following
formulas:
P ¼  107 ln 1 CR
CEQ
 
VD
1X
1
At
;
CEQ ¼ CRVRð Þþ CRVDð ÞVR þVD ;
where X¼VD/VR; CR and CD are ﬁnal concentrations in receiver and donor side,
respectively; VR and VD are volumes in receiver and donor compartment,
respectively; A is the area (cm2) and t is the incubation time (s). The considered
cut-off values are as follows: High: P4200 nm s 1; Medium: 10 nm s 1
oPo200 nm s 1; Low: Po10 nm s 1.
Ethics statement. All the experiments were ethically reviewed and approved by
the GlaxoSmithKline Diseases of the Developing World (DDW) Group Ethical
Committee on Animal Research and were conducted according to Spanish legis-
lation, European Directive 2010/63/EU and GlaxoSmithKline policy on the Care,
Welfare and Treatment of Laboratory animals.
Compounds and controls. Compounds were dissolved in 100% DMSO and dis-
pensed in the 384-well plates using an Echo-CRS liquid handler. Compounds were
tested in 2–3 independent experiments. For each assay, both positive (a drug highly
effective against the biological process) and negative (the vehicle consisting in 0.5%
DMSO) controls were added and a minimum of ten wells per plate were analysed.
Based on that, Z0 factor was calculated for each plate and only those ones with
values higher than 0.4 were considered acceptable for data analysis.
Data analysis. Data were normalized to percentage of inhibition of the biological
response by using positive (that is, highest inhibition achieved by a drug, ICtrl2) or
negative (that is, lowest inhibition achieved in the absence of drug but in presence
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of the vehicle 0.5% DMSO, ICtrl1) controls following the equation described below:
% Inhibition ¼ 100 XCtrl2
Ctrl1Ctrl2100
 
;
where X is the inhibition of measured process for the compound X. Ctrl1 and Ctrl2
are calculated as the average of replicates in the same microtiter plate where
compound X is tested.
Assay performance statistics, such as signal to background ratio, Z0 and robust
3 s.d. activity cut-off were calculated using templates in ActivityBase XE (IDBS,
Guilford, Surrey, UK). Hit population analysis and visualization were conducted
using Spotﬁre DecisionSite (Spotﬁre, Inc., Somerville, MA, USA). The pIC50
( log IC50) values were obtained using the ActivityBase XE nonlinear regression
function in the full curve analysis bundle.
Data availability. The GSK TCAMS dataset for P. falciparum whole cell screening
was deposited in ChEMBL-NTD, www.ebi.ac.uk/chemblntd. Additional
chemical structures of compounds described in this study can be found in
https://www.ebi.ac.uk/chembl/index.php/
The authors declare that all relevant data supporting the ﬁndings of this study
are available within the article and its Supplementary Information ﬁles or are
available from the authors on request.
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